Welcome to our dedicated page for Ispecimen news (Ticker: ISPC), a resource for investors and traders seeking the latest updates and insights on Ispecimen stock.
iSpecimen Inc. (NASDAQ: ISPC) operates a global technology platform connecting life science researchers with healthcare providers to streamline biospecimen procurement. This page aggregates official company announcements, financial disclosures, and operational updates critical for understanding its role in advancing medical research.
Investors and stakeholders gain real-time access to press releases covering strategic partnerships, regulatory milestones, and marketplace expansions. Key updates include earnings reports, technology innovations like the Next Day Quote program, and collaborations enhancing global specimen availability.
Bookmark this page for timely insights into iSpecimen’s progress in addressing biospecimen sourcing challenges. Regular updates ensure you stay informed about developments impacting oncology research, infectious disease studies, and the company’s growing healthcare network.
iSpecimen (Nasdaq: ISPC), a marketplace for human biospecimens, has secured contracts to support advanced COVID-19 research focusing on transmissibility and variant outcomes. The company has partnered with various research organizations over the past ten months, providing samples like nasal swabs and blood products. Notably, iSpecimen has supplied 600 positive and 100 negative serum samples to the CDC for antibody monitoring. Their work extends to military and private organizations, facilitating custom COVID-19 collections across diverse demographics to aid ongoing studies.
iSpecimen reported strong financial results for Q3 2021, with revenue increasing by 21% to $2.7 million, driven by expanding sales efforts and a growing user base. The company's nine-month revenue surpassed $8.6 million, a 57% increase compared to 2020. Notably, unique suppliers increased to 197 and registered users in the marketplace grew 30% year-over-year. Despite increasing general and administrative expenses to $1.7 million, the net loss reduced to approximately $1.1 million. iSpecimen aims to broaden its offerings and enhance its technology moving forward.
iSpecimen Inc. (Nasdaq: ISPC) announces participation in two virtual conferences in November 2021: A.G.P.'s Biotech & Specialty Pharma Conference on November 10 and the 12th Annual Craig-Hallum Alpha Select Conference on November 16. These events will provide opportunities for one-on-one meetings with management. iSpecimen specializes in connecting life scientists to human biospecimens through a unique online marketplace and cloud-based technology, enhancing medical discovery efforts. For more details, visit www.ispecimen.com.
iSpecimen Inc. (NASDAQ: ISPC) will announce its third quarter financial results on November 4, 2021, before market open. The conference call is scheduled for 8:30 a.m. ET, featuring remarks from CEO Christopher Ianelli, CFO Tracy Curley, and COO Jill Mullan. Interested individuals can join the call via toll-free numbers or access a replay until November 18, 2021. The company provides an online marketplace for human biospecimens, connecting scientists with healthcare providers for medical research.
iSpecimen Inc. (Nasdaq: ISPC) announced an expansion of its human biospecimen supplier network to enhance the availability of whole blood, plasma, and biofluids for liquid biopsy development. This move aims to support a growing market projected to reach $1.45 billion with a 24% annual growth rate through 2026. The company has supplied thousands of biospecimens for nearly 30 studies, reinforcing its commitment to advancing liquid biopsy technology, which offers less invasive disease detection methods.
iSpecimen Inc. (Nasdaq: ISPC) announced its inclusion in the Russell Microcap Index, effective September 20, 2021. This inclusion signifies recognition of the company's growth in the biospecimen procurement sector, expected to enhance visibility within the investment community. Being part of the Russell indexes, which benchmark approximately $10.6 trillion in assets, positions iSpecimen favorably for attracting institutional investors. The company is also refining its iSpecimen Marketplace, aiming to support researchers in scientific discovery.
iSpecimen (Nasdaq: ISPC), a leader in the online marketplace for human biospecimens, announced CEO Christopher Ianelli will participate in the H.C. Wainwright 23rd Annual Global Investment Conference, occurring virtually from September 13-15, 2021. His presentation will be available on-demand starting September 13 at 7:00 a.m. ET. iSpecimen connects life scientists with healthcare providers through its innovative platform to facilitate medical discovery.
iSpecimen Inc. (ISPC) announced a growth in its cancer-related supplier network despite challenges posed by COVID-19. The company formed partnerships with various labs and biobanks, significantly enhancing access to tissue and biofluid specimens from cancer patients. A recent collaboration with a European healthcare organization adds 17 types of cancer specimens, expanding the network to over 30 suppliers. These developments are aimed at improving specimen availability for cancer research, supporting advancements in therapies and diagnostics.
iSpecimen Inc. (Nasdaq: ISPC) announced that CEO Dr. Christopher Ianelli will be interviewed on The RedChip Money Report® on Bloomberg TV, airing at 7 p.m. ET on August 14, 2021. This program reaches approximately 73 million homes in the U.S. and offers insights on small-cap investing and interviews with industry leaders. The company provides an online marketplace for human biospecimens, linking life scientists with healthcare providers through its cloud-based technology. More details are available at www.ispecimen.com.
iSpecimen Inc. (ISPC) reported a 93% revenue growth year-over-year, reaching $2.9 million for Q2 2021. The company completed its IPO, raising approximately $18.2 million in net proceeds. It also expanded its registered research users by 40%, totaling over 3,800. However, iSpecimen experienced a net loss of approximately $1.4 million, attributed to increased operating expenses post-IPO. The company aims to enhance its marketplace capabilities while addressing rising costs from specimen procurement.
FAQ
What is the current stock price of Ispecimen (ISPC)?
What is the market cap of Ispecimen (ISPC)?
